Home/Pipeline/Satiro Tablets

Satiro Tablets

Tuberculosis

RegistrationActive (In-licensed for Japan)

Key Facts

Indication

Tuberculosis

Phase

Registration

Status

Active (In-licensed for Japan)

Company

KYORIN Pharmaceutical

About KYORIN Pharmaceutical

KYORIN Pharmaceutical is a publicly listed Japanese pharmaceutical leader with a mission to contribute to people's health by addressing unmet medical needs. Founded in 1923 and publicly listed in 1999, the company has achieved significant scale with a market valuation of ~$94.8B, built on a foundation of established products in respiratory and urology. Its current strategy, outlined in the 'Vision 110' long-term plan, focuses on transforming its business structure to become a core innovator in new pharmaceuticals while expanding its healthcare portfolio.

View full company profile

Therapeutic Areas

Respiratory Urology Otolaryngology Infectious Disease Pain

Other Tuberculosis Drugs

Drug	Company	Phase	Status
Isoniazid Oral Solution, USP	CMP Pharma	Approved	Marketed
Tuberculosis Program	Fimbrion Therapeutics	Preclinical	Active
Undisclosed Program	Crestone	Preclinical	Active
Tuberculosis Diagnostic	GenEndeavor	Research/Exploratory	Active
TB Screening LFA	DiagMetrics	Development	Active
RGFields for Tuberculosis	Anapole Technologies	Pre-clinical	Active
Tuberculosis Nanobody	VicuTec Biologicals	Pre-clinical	Active
Tuberculosis Treatment Monitoring	The eNose Company	Research	Active
ALF Platform	Senzo	Pre-clinical	Active